These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 6424474)

  • 21. Plasma progesterone levels during long-term treatment with levonorgestrel silastic implants.
    Croxatto HB; Diaz S; Pavez M; Miranda P; Brandeis A
    Acta Endocrinol (Copenh); 1982 Oct; 101(2):307-11. PubMed ID: 6814139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel.
    Landgren BM; Johannisson E; Xing S; Aedo AR; Diczfalusy E
    Contraception; 1985 Dec; 32(6):581-601. PubMed ID: 3937664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three-year experience with NORPLANT subdermal contraception.
    Sivin I; Sanchez FA; Diaz S; Holma P; Coutinho E; McDonald O; Robertson DN; Stern J
    Fertil Steril; 1983 Jun; 39(6):799-808. PubMed ID: 6406273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Menstrual blood loss with contraceptive subdermal levonorgestrel implants.
    Nilsson CG; Holma P
    Fertil Steril; 1981 Mar; 35(3):304-6. PubMed ID: 6781939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contraception with progestagens in systemic lupus erythematosus.
    Mintz G; Gutiérrez G; Delezé M; Rodríguez E
    Contraception; 1984 Jul; 30(1):29-38. PubMed ID: 6434228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel.
    Elkik F; Basdevant A; Jackanicz TM; Guy-Grand B; Mercier-Bodard C; Conard J; Bardin CW; Corvol P
    J Clin Endocrinol Metab; 1986 Jul; 63(1):29-35. PubMed ID: 3086360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholesterol and HDL-cholesterol values in women during use of subdermal implants releasing levonorgestrel.
    Holma P; Robertson DN
    Contraception; 1985 Aug; 32(2):163-71. PubMed ID: 3935372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical evaluation of the Capronor contraceptive implant: preliminary report.
    Darney PD; Monroe SE; Klaisle CM; Alvarado A
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1292-5. PubMed ID: 2497647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study.
    Sivin I; Campodonico I; Kiriwat O; Holma P; Diaz S; Wan L; Biswas A; Viegas O; el din Abdalla K; Anant MP; Pavez M; Stern J
    Hum Reprod; 1998 Dec; 13(12):3371-8. PubMed ID: 9886517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The interaction between sex hormone binding globulin and levonorgestrel released from vaginal rings in women.
    Cekan SZ; Jia M; Landgren BM; Diczfalusy E
    Contraception; 1985 Apr; 31(4):431-9. PubMed ID: 3924477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hormonal contraception: new long-acting methods.
    Liskin L; Blackburn R
    Popul Rep K; 1987; (3):K57-87. PubMed ID: 3111901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the effects of NORPLANT capsules and NORPLANT-2 rods on clinical chemistry: metabolic changes.
    Singh K; Viegas OA; Ratnam SS
    Ann Acad Med Singap; 1990 Nov; 19(6):833-6. PubMed ID: 2130749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices.
    Sivin I; Stern J; Diaz S; Pavéz M; Alvarez F; Brache V; Mishell DR; Lacarra M; McCarthy T; Holma P
    Am J Obstet Gynecol; 1992 Apr; 166(4):1208-13. PubMed ID: 1566771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NORPLANT contraceptive implants advancing.
    Segal SJ
    Netw Res Triangle Park N C; 1984; 5(3):1-3. PubMed ID: 12279797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A subdermal progestin implant for long-term contraception.
    Med Lett Drugs Ther; 1991 Mar; 33(839):17-8. PubMed ID: 1899898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Long acting hormonal contraception].
    Garza Flores J; Morales del Olmo A; Martínez M
    Ginecol Obstet Mex; 1990; 58 Suppl 1():1-8. PubMed ID: 2125962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of a biodegradable contraceptive capsule (Capronor) containing levonorgestrel on gonadotropin, estrogen, and progesterone levels.
    Ory SJ; Hammond CB; Yancy SG; Hendren RW; Pitt CG
    Am J Obstet Gynecol; 1983 Mar; 145(5):600-5. PubMed ID: 6402933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
    Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
    Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel.
    Mishell DR; Moore DE; Roy S; Brenner PF; Page MA
    Am J Obstet Gynecol; 1978 Jan; 130(1):55-62. PubMed ID: 619648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.